Skip to main content
. 2003 Dec 5;100(26):15836–15841. doi: 10.1073/pnas.2536558100

Fig. 1.

Fig. 1.

Tumor volumes in nude mice bearing DMS-153 human SCLC during treatment with the GHRH antagonists JV-1-65, JV-1-63, and BN/GRP antagonist RC-3940-II alone or in combination with JV-1-65, all at a dose of 10 μg/day per animal. Vertical bars indicate SEM. *, P < 0.05 vs. control; **, P < 0.01 vs. control; †, P < 0.05 vs. RC-3940-II.